CJC-1295 Medicine An unrolled scroll · 一巻

PART VI — THE SHELF

巻 I · KAN I

CJC-1295: References and Citations

The full reference list underwriting this editorial scroll on CJC-1295. Peer-reviewed primary papers, analytical method papers, regulatory documents, and trial registrations — each cited inline, each linked here with DOI or PubMed URL.

I. · How to read this shelf

How to read this shelf

Every quantitative claim across this CJC-1295 scroll — every half-life value, every dose figure, every adverse-event frequency, every mechanism statement — is keyed to a numbered citation in this index. The two load-bearing peer-reviewed papers are Teichman 2006 (the human Phase 1 PK/PD paper) and Jetté 2005 (the preclinical pharmacology paper that identified CJC-1295 from a set of maleimido bioconjugates). The analytical literature (Henninge 2010, Timms 2019, Memdouh 2021) underwrites the modern WADA detection capability. Regulatory sources (the 2024 PCAC briefing, the WADA Prohibited List) frame the compound's current legal and approval status.

Plate VIII: ten quiet sumi-e vertical rectangles suggesting a shelf of scroll volumes beneath a hairline rule with a vermillion seal on rice paper
Plate VIII · 図八 · The references shelfA shelf of ten quiet scroll-volumes — the published record on CJC-1295 indexed below.

References

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.doi:10.1210/jc.2005-1536 · PMID 16352683 · https://pubmed.ncbi.nlm.nih.gov/16352683/
  2. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058.doi:10.1210/en.2004-1286 · PMID 15817669 · https://pubmed.ncbi.nlm.nih.gov/15817669/
  3. Jetté L, Léger R, Thibaudeau K, et al. Identification of CJC-1295 as a long-lasting GRF analog: rat anterior pituitary cell pharmacology and in vivo plasma persistence (preclinical findings). Endocrinology. 2005;146(7):3052-3058.doi:10.1210/en.2004-1286 · PMID 15817669 · https://pubmed.ncbi.nlm.nih.gov/15817669/
  4. Jetté L, Léger R, et al. DPP-IV resistance and extended in vitro plasma stability of tetrasubstituted GHRH(1-29) (preclinical PK data, same source as ref 2/3). Endocrinology. 2005;146(7):3052-3058.doi:10.1210/en.2004-1286 · PMID 15817669 · https://pubmed.ncbi.nlm.nih.gov/15817669/
  5. Zhou F, Zhang H, Cong Z, Zhao L-H, Zhou Q, Mao C, Cheng X, Xu HE, et al. Structural basis for activation of the growth hormone-releasing hormone receptor. Nat Commun. 2020;11(1):5205.doi:10.1038/s41467-020-18945-0 · PMID 33060564 · https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567103/
  6. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat. J Clin Endocrinol Metab. 2010;95(9):4291-4304.doi:10.1210/jc.2010-0490 · PMID 20554713 · https://pubmed.ncbi.nlm.nih.gov/20554713/
  7. aidsmap (NAM Publications). Lipodystrophy study halted after patient death. News report on ConjuChem Phase II program. 2006.https://www.aidsmap.com/news/jul-2006/lipodystrophy-study-halted-after-patient-death
  8. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650.doi:10.1002/dta.233 · PMID 21204297 · https://pubmed.ncbi.nlm.nih.gov/21204297/
  9. Timms M, Hall N, Levina V, Vine J, Steel R. A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS. Drug Test Anal. 2019;11(7):1085-1093.doi:10.1002/dta.2599 · https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.2599
  10. Veldhuis JD, Bowers CY. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Endocrinol Metab. 2009;296(5):E1085-E1092.doi:10.1152/ajpendo.91001.2008 · PMID 19240251 · https://pubmed.ncbi.nlm.nih.gov/19240251/
  11. Bridon DP, ConjuChem Inc. Drug Affinity Complex (DAC) technology overview. 2005.https://www.conjuchem.com/technology/dac.html
  12. Modified GRF (1-29) pharmacology overview. Review article citing original GHRH analog pharmacology literature. 2024.https://en.wikipedia.org/wiki/Modified_GRF_(1-29)
  13. Jetté L, Léger R, et al. Albumin-bound CJC-1295 immunoreactivity in rat plasma — appears within 15 minutes, persists beyond 72 hours (preclinical PK data, same source as ref 2/3). Endocrinology. 2005;146(7):3052-3058.doi:10.1210/en.2004-1286 · PMID 15817669 · https://pubmed.ncbi.nlm.nih.gov/15817669/
  14. World Anti-Doping Agency. The 2025 Prohibited List. WADA Code Prohibited List, annual publication. 2025.https://www.wada-ama.org/en/prohibited-list
  15. ConjuChem Biotechnologies (sponsor). A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. ClinicalTrials.gov identifier NCT00267527. 2007.https://clinicaltrials.gov/study/NCT00267527
  16. Memdouh S, Gavrilović I, Ng K, Cowan D, Abbate V. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021;13(11-12):1871-1887.doi:10.1002/dta.3183 · PMID 34665524 · https://pubmed.ncbi.nlm.nih.gov/34665524/
  17. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee (PCAC) Meeting; Bulk Drug Substances Nominated for Inclusion on the 503A Bulk Drug Substances List. December 2024 briefing documents.https://www.fda.gov/media/183819/download
  18. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury (NIH). Tesamorelin. NCBI Bookshelf. 2020.https://www.ncbi.nlm.nih.gov/books/NBK548730/
  19. Theratechnologies / U.S. Food and Drug Administration. EGRIFTA (tesamorelin for injection) Full Prescribing Information. FDA Drug Label. 2019.https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022505Orig1s010lbl.pdf